



Association between *Atg5*-dKO signature and patient survival




Association between *Rnf31/Atg5*-dKO signature and patient survival




B

Association between *Atg5*-KO signature and patient survival (excluding IFN responsive genes and cytokines)



Association between *Rnf31/Atg5*-dKO signature and patient survival (excluding IFN responsive genes and cytokines)



**Supplementary Fig. S5. Association of *Atg5*-KO and *Rnf31/Atg5*-dKO signatures with patient survival.**

(A) Kaplan-Meier plots showing the association between *Atg5*-KO and *Atg5/Rnf31*-dKO signatures and patient survival for MHC-I high or MHC-I low tumors in each clinical cohort (overall survival of TCGA melanoma patients and progression-free survival of immune checkpoint blockade-treated melanoma patients).

(B) Kaplan-Meier plots showing the association between refined *Atg5*-KO and *Atg5/Rnf31*-dKO signatures (with IFN-responsive genes and cytokine signaling genes excluded) and patient survival in each clinical cohort (overall survival of TCGA melanoma patients and progression-free survival of immune checkpoint blockade-treated melanoma patients).

The meta-analysis was performed for each association analysis across datasets, with P values indicated on the right side of each panel.